Akkermansia muciniphila AH39

Akkermansia muciniphila AH39

Regulate immunity  | Lose weight

Cell counts: 100 billion cells/g or customized

Recommended dosage: 5 billion cells/day

Why akkermansia

Akkermansia is an oval-shaped gram-negative bacterium. It is an oval-shaped bacterium that is strictly anaerobic, immobile, and does not form endospores. And it is a resident of the human gut, accounting for 3-5% of the human microbiome.

Akkermansia can grow in the intestinal mucus layer and “feed” on the mucin secreted by the host, thereby colonizing the intestinal tract and protecting it from pathogens through competitive exclusion.

Akkermansia has the ability to improve obesity, regulate immunity and improve many metabolic diseases. On July 1, 2019, the results of the first human experiment of Akkermansia probiotic supplements were published in “Nature Medicine”. This human experiment proves that supplementing a certain dose of Akkermansia is safe. No adverse reaction occurred in all the patients and the drug was well tolerated.


The term NGP is broader. and It includes microorganisms present in LBP and microorganisms currently under investigation that have not yet been formulated in the final product. In addition, NGPs can be used both as food supplements such as traditional probiotics and as pharmaceutical products to prevent, treat or cure diseases. Finally, genetically modified microorganisms can also be considered NGPs, although they will most likely be marketed as LBPs.

In 2012, the FDA introduced the term Live Biological Therapeutic Product (LBP), defined as “a biological product” that:

(1) contain living organisms, such as bacteria;

(2) Suitable for the prevention, treatment or cure of human diseases or conditions;

(3) Not a vaccine

LBP is defined in the “European Pharmacopoeia” (Ph.Eur.) as “a medicinal product intended for human use containing live microorganisms (bacteria or yeast)”.